F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
41 hedge funds and large institutions have $93.5M invested in F-star Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 13 increasing their positions, 1 reducing their positions, and 3 closing their positions.
1,200% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 1
929% more call options, than puts
Call options by funds: $247K | Put options by funds: $24K
500% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 3
383% more capital invested
Capital invested by funds: $19.4M → $93.5M (+$74.1M)
58% more funds holding
Funds holding: 26 → 41 (+15)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$14.9M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$8.99M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.53M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.06M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$274K |
| 2 |
SPIA
Steward Partners Investment Advisory
New York
|
-$27.1K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$27K |
| 4 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
-$10K |
FSTX Hedge Fund Activity: Q2 2021 in Review
41 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q2 2021, worth a combined $93.5M — up 383% from $19.4M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new FSTX positions and 3 closed out — a net gain of 15 holders — while 13 added to existing stakes and 1 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $14.9M. The largest seller was Novo Holdings A/S, cutting an estimated $274K.
- 41 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q2 2021, up from 26 in Q1 2021.
- Funds reported $93.5M of F-star Therapeutics, Inc. Common Stock stock for Q2 2021, up 383% quarter-over-quarter.
- 18 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q2 2021 and 3 closed out, a net change of +15 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q2 2021 was Boxer Capital, an estimated $14.9M added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q2 2021 was Novo Holdings A/S, an estimated $274K sold.
Based on aggregated 13F filings for Q2 2021.